Michael Yee, an analyst from UBS, maintained the Buy rating on Eli Lilly & Co. The associated price target remains the same with $1,250.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Yee has given his Buy rating due to a combination of factors tied to Eli Lilly’s competitive position in GLP-1 therapies and the evolving regulatory landscape. He believes the FDA’s move to curb unapproved compounded GLP-1 products reinforces the value of Lilly’s fully approved, clinically validated obesity and diabetes drugs, which already have an established safety and efficacy profile.
Yee also expects that Lilly’s business will see only minimal disruption from compounders, noting that low-cost injectable versions have been available for some time without materially affecting demand for branded products. In his view, stronger FDA enforcement against misleading marketing and unapproved formulations should further protect Lilly’s franchise, supporting sustained revenue growth and justifying a positive stance on the stock.
In another report released on February 6, Bernstein also assigned a Buy rating to the stock with a $1,300.00 price target.
Based on the recent corporate insider activity of 154 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.